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SCIENTIFIC OPINION 
Scientific Opinion on the safety of vitamin D-enriched UV-treated baker’s 
yeast
1 
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)
2,3 
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT 
Following  a  request  from  the  European  Commission,  the  EFSA  Panel  on  Dietetic  Products,  Nutrition  and 
Allergies  (NDA)  was  asked  to  deliver  a  scientific  opinion  on  the  safety  of  ―UV-treated  baker‘s  yeast‖ 
(Lallemand SAS) as a novel food ingredient in the context of Regulation (EC) No 258/97, taking into account 
the comments and objections of a scientific nature raised by Member States. The novel food ingredient (NFI) is 
baker‘s yeast treated with UV irradiation to induce the conversion of ergosterol to vitamin D2. The applicant 
intends to use the NFI during the production of yeast-leavened bread, rolls, fine pastry and food supplements. 
The Panel considers that the provided compositional data, the specification, the data from batch testing, data on 
the stability on the production process are sufficient and do not give rise to safety concerns. The Panel concludes 
that the data provided are sufficient and do not give rise to safety concerns. The applicant intends to use the NFI 
as an alternative source of vitamin D for food supplements and for fortification of yeast-leavened bread, rolls and 
fine pastry at maximum concentrations of 5 μg vitamin D2 per 100 g of these foods. The applicant provided 
combined intake estimates for these two food categories for ―all subjects‖ and ―consumers only‖. The source for 
the production of the NFI is Saccharomyces cerevisiae, an organism with a long history of safe food use. Even if 
the NFI is used at the maximum intended use levels, which deliver 5 µg vitamin D/100 g bread, rolls and fine 
pastry, it is highly unlikely that Tolerable Upper Intake Levels as established by EFSA (EFSA NDA Panel, 
2012)  are  exceeded.  The  Panel  considers  that  UV-treated  baker‘s  yeast  exhibiting  an  enhanced  content  of 
vitamin D2 is safe under the intended conditions of use. 
© European Food Safety Authority, 2014 
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SUMMARY 
Following a request from the European Commission, the EFSA Panel on Dietetic Products, Nutrition 
and Allergies (NDA) was asked to deliver a scientific opinion on the safety of ―UV-treated baker‘s 
yeast‖ (Lallemand SAS) as a novel food ingredient in the context of Regulation (EC) No 258/97, 
taking into account the comments and objections of a scientific nature raised by Member States. 
The  novel  food  ingredient  (NFI)  is  baker‘s  yeast  (Saccharomyces  cerevisiae)  treated  with  UV 
irradiation to induce the conversion of ergosterol to vitamin D2 (ergocalciferol). The applicant intends 
to use the NFI during the production of yeast-leavened bread, rolls, fine pastry and food supplements.  
Vitamin D2 contents in eight lots of the NFI ranged from 2 560 000 to 3 750 000 IU/100 g (640–
940 µg/g); the average content of vitamin D2 in these lots was 3 065 417 IU/100 g, corresponding to 
770 µg/g. The applicant performed analyses to investigate the potential formation of other sterols 
under the conditions employed for the UV treatment of baker‘s yeast. The results of high-performance 
liquid chromatography (HPLC) show that, apart from the intended vitamin D2, tachysterol was the 
only additional sterol detected via HPLC analysis. According to the applicant, the average amounts of 
vitamin D and tachysterol in the vitamin D2 yeast concentrate are 750 μg/g (30 000 IU) and 140 μg/g, 
respectively.  Therefore,  the  production  of  a  bread  product  containing  200 IU/100 g  will  require 
6.67 mg of vitamin D2 yeast concentrate that contains 30 000 IU/g. The 6.67 mg of yeast concentrate 
will provide 0.93 μg of tachysterol/100 g of bread.  
The Panel notes that UV irradiation may result in reactions of biomolecules, such as lipids or proteins. 
However, taking account of (i) the parameters of the UV treatment of baker‘s yeast as performed in 
the course of the production process of the NFI (e.g. the dimensions of the UV irradiation chamber, 
the flow rate of the yeast cream and the employed UV power), (ii) the low levels of potential reaction 
products that might be expected under these conditions from UV-induced reactions, e.g. oxidations of  
yeast lipids or proteins, and (iii) the intended use levels of the NFI, the Panel considers that it is not 
necessary to perform additional analyses for potential products formed from yeast components as a 
result of the UV treatment.  
Stability tests of the NFI and of three types of bread baked with the NFI at 227 °C indicated that there 
was no significant reduction in the levels of vitamin D2 for a period of three years in the NFI and for 
14 days in three bread types which were baked with the NFI. The applicant also provided data on the 
stability of vitamin D2 in two batches of a food supplement stored at 4 °C, 25 °C and 30 °C for 24 
months. The data suggest minimal, if any, loss of vitamin D2 over this period. 
The Panel considers that the provided compositional data, the specification, the data from batch testing 
and the stability of the NFI are sufficient and do not give rise to safety concerns.  
The applicant provided information on the dimensions of the UV irradiation chamber and the electrical 
cabinet, the flow rate of the yeast cream and the employed UV power. The applicant did not provide 
information  on  the  maximum  UV  irradiation  power  applied;  however,  the  Panel  considers  the 
information provided by the applicant in response to the Member State comment on UV treatment 
conditions to be sufficient. The UV treatment step is followed by drying using a fluid bed dryer (yeast 
for baking) or a spray dryer or roller dryer (yeast for supplements). The resulting ―vitamin D2 yeast 
concentrate‖  contains  between  1 800 000 IU/100 g  and  3 500 000 IU/100 g  vitamin  D2,  compared 
with  the  initial  concentration  of  less  than  20 IU  vitamin  D2/100 g.  When  used  for  baking,  this 
concentrate  would  be  blended  with  conventional  yeast  in  order  to  adjust  the intended  amount  of 
vitamin D2 in the final product.   
The Panel considers that, although the UV treatment may result in mutations in the employed baker‘s 
yeast, their low numbers, the conditions of the process and the intended uses of the NFI would not 
allow mutants to become dominant in the final product. Safety of  UV-treated baker‘s yeast 
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According  to  the  applicant,  the  UV-treated  baker‘s  yeast  retains  its  baking  activity;  however,  no 
experimental data were provided.  
The Panel concludes that the data provided on the production process are sufficient and do not give 
rise to safety concerns.  
The applicant intends to use the NFI as an alternative source of vitamin D for food supplements and 
for fortification of yeast-leavened bread, rolls and fine pastry at maximum concentrations of 5 μg 
(200 IE)  vitamin  D2  per  100 g  of  these  foods. The  applicant  used  the  chronic  food  consumption 
statistics  of  the  EFSA  Comprehensive  Food  Consumption  Database  to  estimate  potential  intakes. 
Because  this  database  does  not  include  ―yeast-leavened  fine  pastry‖,  the  applicant  conservatively 
estimated intakes for the broader, superordinate level 2 category ―fine bakery wares‖. ―Rolls‖ are 
covered by the level 2 food category ―bread and rolls‖ in the published chronic food consumption 
statistics of the EFSA Comprehensive Food Consumption Database. The applicant provided combined 
intake estimates for these two food categories for ―all subjects‖ and ―consumers only‖. The highest 
97.5
th percentile consumption for ―consumers only‖ among EU Member States was obtained for ―other 
children‖ (4-10 years; 27.2 µg/day) and adults (36.0 µg/day) from Latvia and for adolescents from 
Germany (35.5 µg/day). 
According to EFSA‘s opinion on upper levels for vitamin D from 2012, high percentile intakes of 
vitamin D from the diet of young children, adolescents and adults vary from 2.4 to 11.9, from 3.0 to 
7.7 and from 2.4 to 16.9 µg/day respectively. 
Regarding food supplements, the applicant considers the use of the NFI in food supplements as a 
direct  ―like  for  like‖  replacement  for  existing  vitamin  D2  ingredients  and,  as  such,  will  it  not 
significantly add to the level of vitamin D consumed by individuals via supplements. The use level of 
the NFI intended by the applicant for food supplements is 5 µg/day.  
The Panel notes that the type of intake estimate provided by the applicant assumes that all consumed 
food products within a food category contain the ingredient at the maximum specified level of use. It 
is also noted that the combined high percentile intake from the two level 2 food categories (―breads 
and rolls‖ and ―fine bakery wares‖) based on summary statistics is expected to over-estimate intakes. 
Third, among the level 2 food category ―fine bakery wares‖ the applicant intends to use the NFI only 
in ―yeast-leavened fine pastry‖, but the intake estimate is based on intakes for the complete level 2 
category ―fine bakery wares‖, although many products in this category do not contain yeasts. The 
Panel  therefore  considers  that  the  applicant‘s  intake  estimate  significantly  over-estimates  intakes. 
However, even if it is conservatively assumed that all consumed yeast-containing bread, rolls and fine 
pastry are fortified with the NFI at the maximum intended use levels, which deliver 5 µg vitamin 
D/100 g of these foods, it is highly unlikely that Tolerable Upper Intake Levels established by EFSA 
(EFSA  NDA  Panel,  2012)  for  children  aged  1–10  years  (50 µg/day)  and  adults  (100 µg/day)  are 
exceeded. 
The applicant has not carried out any toxicological studies on the product to which the application 
applies. The Tolerable Upper Intake Levels for vitamin D were set by EFSA at 100 μg/day for adults 
and adolescents (10–18 years), at 50 μg/day for children (1–10 years) and at 25 μg/day for infants (up 
to  1  year)  (EFSA,  2012).  Given  the  source,  nature  and  the  intended  uses  of  the  NFI,  the  Panel 
considers that the absence of toxicological studies with the NFI is acceptable.   
The  Panel  considers  that the  risk  of  allergic  reactions  to the  NFI  cannot be ruled  out  but is not 
dissimilar to the risk associated with conventional baker‘s yeast (S. cerevisiae).  
The source for the production of the NFI is S. cerevisiae, an organism with a long history of safe food 
use. EFSA has categorised S. cerevisiae as a microorganism that has Qualified Presumption of Safety 
status. Treatment with UV is employed to induce the conversion of the endogenous ergosterol into 
vitamin D2. The NFI is intended for use in the production of yeast-leavened bread, rolls and fine Safety of  UV-treated baker‘s yeast 
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pastry and in food supplements. Even if the NFI is used at the maximum intended use levels, which 
deliver 5 µg vitamin D/100 g bread, rolls and fine pastry, it is highly unlikely that Tolerable Upper 
Intake Levels as established by EFSA (EFSA NDA Panel, 2012) will be exceeded.  
The Panel considers that UV-treated baker‘s yeast exhibiting an enhanced content of vitamin D2 is 
safe under the intended conditions of use. 
 Safety of  UV-treated baker‘s yeast 
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BACKGROUND AS PROVIDED BY THE EUROPEAN COMMISSION 
On 4 May 2012, the company Lallemand SAS submitted a request under Article 4 of the Novel Food 
Regulation  (EC)  N°  258/97  to  place  on  the  market  ‗UV  treated  baker‘s  yeast‘  as  a  novel  food 
ingredient (NFI). 
On 31 August 2012, the competent authorities of the United Kingdom forwarded to the Commission 
their  initial  assessment  report,  which  came  to  the  conclusion  that  the  UV-treated  baker‘s  yeast 
exhibiting an enhanced content of vitamin D is acceptable as a novel food ingredient at the proposed 
uses and use levels.  
On 11 September 2012, the Commission forwarded the initial assessment report to the other Member 
States. Several of the Member States submitted comments or raised objections. 
The concerns of a scientific nature raised by the Member States can be summarised as follows: 
  The product specifications should specify the maximum tachysterol content.  
  The specifications of UVB including maximum radiation intensity used in the production of 
vitamin D-enriched yeast through UVB irradiation were requested. 
  The applicant should provide information on possible effects of the UV treatment in the yeast 
and evaluate the presence of potential undesirable newly formed components resulting from 
yeast  components,  such  as  lipids  and  proteins.  The  specifications  should  include  safe 
maximum levels for undesirable compounds.   
  No data on ingredients other than tachysterol and ergosterol or comparative analyses with the 
untreated yeast were submitted.  
  It would be useful if the company provided additional information on the stability of vitamin 
D2 in the finished products (food and food supplements). 
  The intake estimate should consider the categories of bread consumed in Europe, including 
France, since categories mentioned in the application come from non-European states [North 
America].  
  The  doses  of  the  NFI  (mg/kg)  added  to  the  dough  used  to  make  bread(s)  to  reach  the 
concentration of vitamin D2 indicated by the applicant should be clearly specified to avoid 
over-dosage of the ingredient by users. 
 Terms of reference as provided by the European Commission  
In accordance with Article 29 (1) (a) of Regulation (EC) No 178/2002, the European Food Safety 
Authority is asked to carry out the additional assessment for ‗UV treated yeast‘ as a food ingredient in 
the context of Regulation (EC) N° 258/97. 
EFSA is asked to carry out the additional assessment and to consider the elements of a scientific 
nature in the comments raised by the other Member States. Safety of  UV-treated baker‘s yeast 
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ASSESSMENT 
In  accordance  with  Commission  Recommendation  97/618/EC,  UV-treated  baker‘s  yeast  has  been 
allocated to Class 2.1, i.e. foods or food ingredients that are ―complex novel foods from non-GMO 
sources. The source of the novel food has a history of food use in the Community‖. The assessment of 
the safety of this novel food ingredient (NFI) is based on data supplied in the original application, the 
initial assessment by the competent authority of the United Kingdom, the concerns and objections of 
the other Member States and the responses of the applicant. The data are required to comply with the 
information required for the novel foods of Class 2.1, i.e. structured schemes I, II, III, IX, XI, XII and 
XIII of Commission Recommendation 97/618/EC. In the text these structured schemes are numbered 1 
to 7. It is noted that the NFI is intended by the applicant to be marketed as yeast (Saccharomyces 
cerevisiae) containing an enhanced level of vitamin D2 for addition to foods, i.e. yeast-leavened bread, 
rolls, fine pastry and food supplements. This assessment concerns only risk that might be associated 
with consumption, and is not an assessment of the efficacy of UV-treated baker‘s yeast with regard to 
any claimed benefit. 
 
1.  Specification of the Novel Food (NF) 
The novel  food  ingredient  (NFI)  is  baker‘s  yeast  (Saccharomyces  cerevisiae)  treated  with  UV to 
induce the conversion of ergosterol to vitamin D2 (ergocalciferol); the structures of the substances are 
shown in Figure 1. The applicant intends to use the NFI during the production of yeast-leavened bread, 
rolls and fine pastry and food supplements.   
Vitamin D2: 
Chemical name: (5Z,7E,22E)-3S-9,10-secoergosta-5,7,10(19),22-tetraen-3-ol 
Synonym: ergocalciferol 
Chemical Abstract Service Registry Number: 50-14-6.  
Molecular weight: 396.65 Da. 
 
 
 
 
Figure 1:   Structures of ergosterol (I), vitamin D2 (II) and tachysterol (III)  
The specifications proposed by the applicant are given in Table 1. 
O  H 
O  H 
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Table 1:   Specifications of the novel food ingredient 
Parameters  Specification  Methods 
Appearance  Tan-coloured, free-flowing 
granules 
Visual 
Vitamin D2  1 800 000–3 500 000 IU 
vitamin D/100 g 
(a) 
(450–875 µg/g) 
Adapted AOAC method 982.29  (AOAC, 
2000) 
Coliforms
  <1 000/g  FDA Bacteriological Analytical Manual 
E. coli  <10/g  FDA Bacteriological Analytical Manual 
Salmonella  Absent/25 g  FDA Bacteriological Analytical Manual 
(a):  1 mg of vitamin D corresponds to 40 000 IU. 
 
Data demonstrating the validation of the method employed for the quantification of vitamin D2 have 
been provided. 
The vitamin D2 content in eight lots of the NFI ranged from 2 560 000 to 3 750 000 IU/100 g (640–
940 µg/g); the average content of vitamin D2 in these lots was 3 065 417 IU/100 g, corresponding to 
770 µg/g. 
It  is  known  that  the  UV-induced  conversion  of  ergosterol  into  vitamin  D2  is  accompanied  by 
photochemical isomerisations resulting in by-products such as tachysterol and lumisterol (Havinga et 
al., 1960); the structure of tachysterol is shown in Figure 1. Analogous products are known to be 
formed in the course of the UV-induced conversion of epidermal 7-dehydrocholesterol into vitamin 
D3 (Holick et al., 1981). The applicant, therefore, performed analyses to investigate the potential 
formation of these sterols under the conditions employed for the UV treatment of baker‘s yeast. The 
results of HPLC show that, apart from the intended vitamin D2, tachysterol was the only additional 
sterol detected by HPLC analysis. An external laboratory contracted by the applicant quantified the 
levels present in two commercial lots. Tachysterol levels were found to be 140 and 145 µg/g, and 
vitamin D2 levels were found to be 672 and 825 µg/g. All other minor peaks were also present prior to 
UV treatment. According to the applicant, the average amounts of vitamin D and tachysterol in the 
vitamin  D2  yeast  concentrate  are 750 μg/g  (30,000 IU)  and  140 μg/g,  respectively.  Therefore, the 
production  of a  bread  product  containing  200 IU/100 g  will  require  6.67 mg  of  vitamin  D2  yeast 
concentrate  that  contains  30 000 IU/g.  The  6.67 mg  of  yeast  concentrate  will  provide  0.93 μg  of 
tachysterol/100 g of bread. Therefore, the Panel does not consider it necessary to include tachysterol 
in the product specification. 
The Panel notes that UV irradiation may result in reactions of biomolecules, such as lipids or proteins. 
However, taking into account (i) the parameters of the UV treatment of baker‘s yeast as performed in 
the course of the production process of the NFI (e.g. the dimensions of the UV irradiation chamber, 
the flow rate of the yeast cream and the employed UV power), (ii) the low levels of potential reaction 
products that might be expected under these conditions from UV-induced reactions, e.g. oxidations of  
yeast lipids or proteins, and (iii) the intended use levels of the NFI, the Panel considers that it is not 
necessary to perform additional analyses for potential products formed from yeast components as a 
result of the UV treatment.  
Analysis of three lots of vacuum-packed vitamin D2 yeast concentrate indicated that there was no 
significant reduction in the level of vitamin D2 over a three-year period. In response to a request by 
Member  States,  the  applicant  provided  data  on  the  vitamin  D2  content  in  eight  samples  of  two 
different bread types (four white bread, four wholewheat bread) after 4 and 14 days of storage and 
compared the contents of vitamin D2 in the four dough formulations. One of each of the bread types 
was produced with untreated baker‘s yeast. These results indicate that no significant vitamin D2 Safety of  UV-treated baker‘s yeast 
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loss occurred during the bread-making process, including baking at 227 °C and storage of the 
bread for at least 14 days. 
The applicant also provided data on the stability of vitamin D2 in two batches of a food supplement 
stored at 4 °C, 25 °C and 30 °C for 24 months. The data suggest minimal, if any, loss of vitamin D2 
over this period. 
The Panel considers that the provided compositional data, the specification, the data from batch testing 
and the stability of the NFI are sufficient and do not give rise to safety concerns.  
2.  Effect of the production process applied to the NFI   
The  applicant  has  a  long  experience  in  producing  baker‘s  yeast.  Details  of  the  commercially 
performed  fermentation,  critical  process  parameters  and  quality  assurance  measures  have  been 
provided.   
The yeast cream resulting from the fermentation step is continuously pumped past UV lamps (254 nm)  
for  a  certain  period  of  time.  The  applicant  provided  information  on  the  dimensions  of  the  UV 
irradiation chamber and the electrical cabinet, the flow rate of the yeast cream and the employed UV 
power. The applicant did not provide information on the maximum UV irradiation power applied; 
however, the Panel considers the information provided by the applicant in response to the Member 
State comment on UV treatment conditions to be sufficient. The UV treatment step is followed by 
drying  using  a  fluid  bed  dryer  (yeast  for  baking)  or  a  spray  dryer  or  roller  dryer  (yeast  for 
supplements). The resulting ―vitamin D2 yeast concentrate‖ contains between 1 800 000 IU/100 g and 
3 500 000 IU/100 g vitamin D2, compared with the initial concentration of less than 20 IU vitamin 
D2/100 g. When used for baking, this concentrate would be blended with conventional yeast in order 
to adjust the intended amount of vitamin D2 in the final product.   
All production steps are certified according to the International Organization for Standardization (ISO) 
and operated in accordance with Good Manufacturing Practice (GMP).  
Each production lot of the concentrate is analysed by an external laboratory regarding the content of 
vitamin D2. Microbiological analyses are performed in-house following internationally recognised 
methods. Certificates of analysis have been provided for three batches, all complying with the product 
specifications.  
UV radiation at a wavelength of 254 nm, as used in this process, will induce mutations in DNA in 
surviving  cells, albeit in very  low  numbers. The  applicant  used  RAPD-PCR  (randomly  amplified 
polymorphic  DNA)  and  RFLP  (restriction  fragment  length  polymorphism)  DNA  fingerprinting 
techniques to screen for chromosomal rearrangements and point mutations in the UV-treated baker‘s 
yeast.  These  methods  did  not  reveal  differences  between  the  UV-treated  yeast  and  the  control 
(Bertrand, 2010). 
The Panel considers that, although the UV treatment may result in mutations in the employed baker‘s 
yeast, their low numbers, the conditions of the process and the intended uses of the NFI would not 
allow mutants to become dominant in the final product. 
According  to  the  applicant,  the  UV-treated  baker‘s  yeast  retains  its  baking  activity;  however,  no 
experimental data were provided.  
The Panel concludes that the data provided on the production process are sufficient and do not give 
rise to safety concerns.  Safety of  UV-treated baker‘s yeast 
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3.  History of the organism used as a source  
Saccharomyces cerevisiae has an extensive history of food use in the baking and brewing industries. 
EFSA  has  categorised  S.  cerevisiae  as  a  microorganism  that  has  QPS  (Qualified  Presumption  of 
Safety) status (EFSA BIOHAZ Panel, 2013).  
4.  Anticipated intake/extent of the use of the NF 
The applicant intends to use the NFI as an alternative source for vitamin D for fortification in foods 
which contain yeast and for food supplements.  The original dossier suggested that the NFI be added at 
use levels which provide 5 μg vitamin D2 per 100 g of various bread types such as white bread, 
wholemeal  bread,  brown,  granary  and  wheatgerm  bread  and  other  yeast-leavened  breads.  The 
applicant indicated that bread will be formulated by using blends of UV-treated and untreated baker‘s 
yeast to ensure that, irrespective of the level of vitamin D2 present in individual batches of the yeast 
concentrate,  it  would  contain  a  maximum  of  5 µg  vitamin  D2  (200 IU)  per  100 g.  Based  on  the 
specification (Table 1), 5 µg of vitamin D2 is equivalent to between 5.7 and 11 mg of the UV-treated 
yeast. The intended use levels for the NFI in food supplements would deliver 5 μg vitamin D2 per day. 
The original dossier contained intake estimates based on UK NDNS data only for bread fortified with 
the NFI. According to these data, the mean and P97.5
th percentile intake estimates for children (with 
an age of 4–18 years) would be 3.6 and 8.6 µg/day, respectively, if all consumed bread was fortified 
with  the  NFI;  for  adults  vitamin  D  intakes  from  fortified  bread  would  be  4.5  and  10.8 µg/day, 
respectively. 
During the evaluation by EFSA, the applicant requested that this NFI also be authorised for use for 
fortification of yeast-leavened rolls and yeast-leavened fine pastry at maximum concentrations of 5 μg 
vitamin D2 per 100 g of these foods. At the request of EFSA, the applicant therefore provided an 
intake estimate which covers also potential intakes from yeast-leavened rolls and yeast-leavened fine 
pastry. The applicant used the chronic food consumption statistics of the EFSA Comprehensive Food 
Consumption  Database.
4  Because this database does not  include ―yeast-leavened  fine  pastry‖,  the 
applicant conservatively estimated intakes for the broader, superordinate level 2 category ―fine bakery 
wares‖. ―Rolls‖ are covered by the level 2 food category ―bread and rolls‖ in the published chronic 
food consumption statistics of the EFSA Comprehensive Food Consumption Database.   
Table 2 (all subjects) and Table 3 (consumers only) provide combined daily intake estimates for the 
two level 2 food categories ―bread and rolls‖ and ―fine bakery wares‖ and for vitamin D2 from these 
foods fortified with the NFI (Appendix). 
The highest 97.5 percentile for among EU Member States was obtained for ―other children‖ (4-10 
years;  27.2 µg/day)  and  adults  (36.0 µg/day)  from  Latvia  and  adolescents  from  Germany 
(35.5 µg/day). 
Regarding food supplements, the applicant considers the use of the NFI in food supplements as a 
direct  ―like  for  like‖  replacement  for  existing  vitamin  D2  ingredients  and,  as  such,  will  not 
significantly add to the level of vitamin D consumed by individuals via supplements. The use level of 
the NFI intended by the applicant for food supplements is 5 µg/day. 
Vitamin D intakes from the diet  
In 2012, EFSA estimated that the mean percentile intake of vitamin D from foods among  young 
children varies from 1.7 µg/day (Denmark, boys, 1–3 years) to 5.6 µg/day (Greece, 1.5 years) while 
the high percentile intake estimates vary from 2.4 µg/day (Denmark, 95
th percentile, boys, 1–3 years) 
to 11.9 µg/day (Greece, 90
th percentile, 1–5 years) (EFSA NDA Panel, 2012).  
                                                       
4  http://www.efsa.europa.eu/en/datexfooddb/docs/datexfooddbchronicgday.xls 
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In adolescents, mean intake from foods varies from 1.6 μg/day (Spain, 11–17 years) to 4.0 μg/day 
(Belgium, boys 13–18 years). Intakes at the 95
th
 percentile were between 3.0 μg/day (Spain, 11–17 
years) and 7.7 μg/day (Italy, boys, 10 to < 18 years, including fortified food). Mean or median intakes 
from foods and supplements and for the 95
th
 percentile of consumption are within these ranges. 
For adults, estimates of mean intake vitamin D from foods varied from 1.1 μg/day (Spain, women, 18–
64 years) to 8.2 μg/day (Finland, men, 2–74 years) and estimated 95
th percentile intakes varied from 
2.4 μg/day (Spain, women, 1–64 years) to 16.0 μg/day (Finland, men, 25–74 years). For those adults 
who consume vitamin D also from food supplements, intakes were estimated to be 1.5-fold higher. 
The Panel notes that the type of intake estimate provided by the applicant assumes that all consumed 
food products within a food category contain the ingredient at the maximum specified level of use. It 
is also noted that the combined high percentile intake from the two level 2 food categories (breads and 
rolls and fine bakery wares) based on summary statistics is expected to over-estimate intakes. Third, 
among the level 2 food category ―fine bakery wares‖ the applicant intends to use the NFI only in 
―yeast-leavened fine pastry‖, but the intake estimate is based on intakes for the complete level 2 
category ―fine bakery wares‖, although many products in this category do not contain yeasts. The 
Panel  therefore  considers  that  the  applicant‘s  intake  estimate  significantly  over-estimates  intakes. 
However, even if it is conservatively assumed that all consumed yeast-containing bread, rolls and fine 
pastry are fortified with the NFI at the maximum intended use levels, which deliver 5 µg vitamin 
D/100 g of these foods, it is highly unlikely that tolerable upper intake levels established by EFSA 
(EFSA NDA Panel, 2012) for children aged 1–10 years (50 µg/day) and adults (100 µg/day) will be 
exceeded. 
5.  Information from previous exposure to the NF or its source 
Both the source of the NFI, i.e. S. cerevisiae, and vitamin D2 have a long history of food use. In 
Canada, the addition of vitamin D2-yeast to yeast-leavened bakery products has been permitted at a 
level of up to 90 IU (2.25 µg) per 100 g of product (Health Canada, 2011). In the USA, the food 
additive regulations have been amended to allow for the safe use of vitamin D2 baker‘s yeast in yeast-
leavened baked products at levels not to exceed 400 IU of vitamin D2 per 100 g of the finished food 
(FDA, 2012).  
6.  Nutritional information on the NF 
Bioavailability of vitamin D2 from bread prepared with the NFI has been investigated in a feeding 
study with growing, vitamin-deficient rats. Plasma 25-hydroxyvitamin D (25OHD) levels increased in 
a dose-dependent manner, but rats fed the bread baked with the vitamin D2-enriched yeast achieved 
lower levels than rats fed vitamin D3 (Hohmann et al., 2011). According to a PowerPoint presentation 
on a four-week trial (carried out in 13 women) provided by the applicant, bread baked with vitamin 
D2-containing yeast had a comparable effect on plasma serum 25OHD concentration as a vitamin D2-
containing supplement (Lamberg-Allardt et al., 2010). 
The bioavailability of vitamin D2 from irradiated mushrooms, in which vitamin D2 is formed from 
endogenous ergosterol in an analogous way to that seen in the UV-treated baker‘s yeast, has also been 
demonstrated in feeding studies with rats using the serum level of 25-hydroxyvitamin D as indicator 
(Jasinghe et al., 2005; Koyyalamudi et al., 2009).  
The Panel notes that current dietary reference values for children aged 1–18 years and for adults vary 
from 5 to 15 µg/day and from 10 to 20 µg/day, respectively (SCF, 1993; IoM, 2011; DACH, 2013; 
NNR, 2013).  
The  Panel  considers that the  NFI  is  not  nutritionally  disadvantageous.  The  Panel  notes  that  high 
percentile intakes estimates provided by the applicant at the proposed uses and use levels exceed 
current international dietary references values for vitamin D. Safety of  UV-treated baker‘s yeast 
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7.  Microbiological information on the NF 
According  to  the  applicant,  every  batch  of  the  NFI  will  be  tested  to  ensure  that  it  meets  the 
microbiological standards and specifications. The Panel considers that the data provided do not give 
rise to concerns with regard to the microbiological quality of the NI. 
8.  Toxicological information on the NF  
The applicant has not carried out any toxicological studies on the product to which the application 
applies.  
The Tolerable Upper Intake Levels for vitamin D were set by EFSA at 100 μg/day for adults and 
adolescents (10–18 years), at 50 μg/day for children (1–10 years) and at 25 μg/day for infants (up to 1 
year) (EFSA NDA Panel, 2012). 
Given the source, nature and the intended uses of the NFI, the Panel considers that the absence of 
toxicological studies with the NFI is acceptable.   
9.  Allergenicity 
The  Panel  considers  that the  risk  of  allergic  reactions  to the  NFI  cannot be ruled  out  but is not 
dissimilar to that associated with conventional baker‘s yeast (S. cerevisiae).  
10.  Discussion 
The source for the production of the NFI is S. cerevisiae, an organism with a long history of safe food 
use. EFSA has categorised S. cerevisiae as a microorganism that has QPS status. Treatment with UV 
irradiation is employed to induce the conversion of the endogenous ergosterol into vitamin D2. Owing 
to  the  nature  of  the  source  and  the  conditions  of  the  manufacturing  process,  the  provided 
compositional data and the proposed specification of the NFI are considered sufficient and do not give 
rise to safety concerns. 
The NFI is intended for use in the production of yeast-leavened bread, rolls and fine pastry and in food 
supplements. The Panel notes that high percentile intakes estimates provided by the applicant at the 
proposed uses and use levels exceed current international dietary references values for vitamin D. 
However, even if the NFI is used at the maximum intended use levels, which deliver 5 µg vitamin 
D/100 g bread, it is highly unlikely that Tolerable Upper Intake Levels as established by EFSA (EFSA 
NDA Panel, 2012) are exceeded.  
CONCLUSIONS 
The Panel considers that UV-treated baker‘s yeast exhibiting an enhanced content of vitamin D2 is 
safe under the intended conditions of use. 
 
DOCUMENTATION PROVIDED TO EFSA 
1.  Dossier ‗Application for the Approval of Vitamin D2 Yeast Concentration)‘ under Regulation 
(EC) No 258/97 of the European Parliament and of the Council of 27 January 1997 Concerning 
Novel  Foods and  Novel  Food  Ingredients‖ received  on  14/02/2013.  Submitted  by  Lallemand. 
Additional data were provided on 28/11/2013 and 02/12/2013. 
2.  Letter from the European Commission to the European Food Safety Authority with the request for 
an opinion on the safety of ‗UV treated yeast‘, received on 05/04/2013; Ref. Ares (2013)542120 – 
04/04/2013.  
3.  Initial assessment report carried out by the Food Safety Authority of the United Kingdom: ‗UV 
treated Baker‘s yeast‘. Safety of  UV-treated baker‘s yeast 
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4.  Member States‘ comments and objections. 
Response by the applicant to the initial assessment report and the Member States‘ comments and 
objections.  
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APPENDIX 
Table 2:   Combined daily intake estimates for foods in the two level 2 food categories ―bread and 
rolls‖ and ―fine bakery wares‖ and for vitamin D2 from the NFI for ―all subjects‖ 
Country  Age class  No of 
subjects 
Mean 
consumption 
(g) 
P97.5 
consumption 
(g) 
Mean 
consumption 
of vitamin D2 
( g) 
P97.5 
consumption 
of vitamin D2 
( g) 
Belgium  Adolescents  584  183.9  517.5  9.2  25.9 
  Adults  1304  174.4  530.5  8.7  26.5 
  Toddlers  36
( a)  109.9  286.5  5.5  14.3 
  Other children 
(b)  625  113.4  266.5  5.7  13.3 
Bulgaria  Toddlers  428  101.0  262.5  5.0  13.1 
  Other children  433  143.5  373.5  7.2  18.7 
Cyprus  Adolescents  303  117.0  296.7  5.8  14.8 
Czech 
Republic 
Other children  389  141.4  359.0  7.1  17.9 
  Adolescents  298  207.9  575.0  10.4  28.8 
  Adults  1 666  222.8  664.0  11.1  33.2 
Germany  Adolescents  1 011  184.3  650.0  9.2  32.5 
  Adults  10 419  194.8  599.0  9.7  30.0 
  Toddlers  84  57.2  152.3  2.9  7.6 
  Other children  223  118.2  295.7  5.9  14.8 
Denmark  Other children  490  146.8  314.4  7.3  15.7 
  Adolescents  479  151.1  335.0  7.6  16.8 
  Adults  2 822  169.2  367.0  8.5  18.4 
Spain  Adults  410  134.0  436.7  6.7  21.8 
  Adolescents  86  170.2  552.8  8.5  27.6 
  Adults  981  133.9  407.8  6.7  20.4 
  Toddlers  17 
(a)  51.7  194.5  2.6  9.7 
  Other children  156  119.4  365.0  6.0  18.3 
  Adolescents  209  194.1  599.5  9.7  30.0 
  Other children  399  139.9  328.5  7.0  16.4 
  Adolescents  651  189.0  492.0  9.4  24.6 
Finland  Adults  1 575  2.2  15.5  0.1  0.8 
  Toddlers  497  2.3  18.3  0.1  0.9 
  Other children  250  129.4  347.3  6.5  17.4 
France  Other children  482  118.1  329.0  5.9  16.4 
  Adolescents  973  157.2  445.6  7.9  22.3 
  Adults  2 276  167.8  484.6  8.4  24.2 
United 
Kingdom 
Adults  1 724  158.9  402.9  7.9  20.1 
Greece  Other children  839  105.3  295.0  5.3  14.8 
Hungary  Adults  1 074  164.7  427.3  8.2  21.4 
Ireland  Adults  958  176.4  445.1  8.8  22.3 
Italy  Toddlers  36  49.1  245.1  2.5  12.3 
  Other children  193  125.1  367.0  6.3  18.4 
  Adolescents  247  160.3  478.4  8.0  23.9 
  Adults  2 313  144.4  422.1  7.2  21.1 
Latvia  Other children  189  129.9  493.0  6.5  24.7 
  Adolescents  470  176.7  622.5  8.8  31.1 
  Adults  1 306  193.9  685.0  9.7  34.3 Safety of  UV-treated baker‘s yeast 
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Country  Age class  No of 
subjects 
Mean 
consumption 
(g) 
P97.5 
consumption 
(g) 
Mean 
consumption 
of vitamin D2 
( g) 
P97.5 
consumption 
of vitamin D2 
( g) 
Netherlands  Adults  750  203.7  535.0  10.2  26.8 
  Toddlers  322  102.8  264.0  5.1  13.2 
  Other children  957  128.7  328.7  6.4  16.4 
Sweden  Adults  1 210  159.0  387.9  8.0  19.4 
  Other children  1 473  110.7  302.8  5.5  15.1 
  Adolescents  1 018  119.6  331.5  6.0  16.6 
(a):  As the number of subjects is lower than 60, the 95th and higher percentiles may not be statistically robust. 
(b):  ―Other children‖ comprises children aged 4 to 10 years.  Safety of  UV-treated baker‘s yeast 
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Table 3:   Combined daily intake estimates for foods in the two level 2 food categories ―bread and 
rolls‖ and ―fine bakery wares‖ and for vitamin D2 from the NFI for ―consumers only‖ 
Country  Age class  No of 
consumers 
Mean 
consumption 
(g) 
P97.5 
consumption  
(g) 
Mean 
consumption of 
vitamin D2 ( g) 
P97.5 
consumption 
of vitamin D2 
( g) 
Belgium  Adolescents  567  205.0  522.6  10.2  26.1 
Belgium  Adults  1262  201.0  545.0  10.0  27.3 
Belgium  Toddlers  36 
(a)  110.7  286.5  5.5  14.3 
Belgium  Other children  624  117.5  267.7  5.9  13.4 
Bulgaria  Toddlers  408  111.7  266.1  5.6  13.3 
Bulgaria  Other children  417  157.0  376.5  7.8  18.8 
Cyprus  Adolescents  296  132.7  311.0  6.6  15.6 
Czech Republic  Other children  387  152.6  359.0  7.6  17.9 
Czech Republic  Adolescents  297  222.2  580.0  11.1  29.0 
Czech Republic  Adults  1 648  255.0  684.0  12.7  34.2 
Denmark  Other children  490  155.5  331.6  7.8  16.6 
Denmark  Adolescents  479  161.6  353.6  8.1  17.7 
Denmark  Adults  2 822  178.4  384.2  8.9  19.2 
Finland  Toddlers  182  7.1  27.0  0.4  1.4 
Finland  Adults  549  10.7  28.0  0.5  1.4 
Finland  Other children  250  131.4  347.3  6.6  17.4 
France  Other children  469  119.7  329.0  6.0  16.4 
France  Adolescents  959  161.0  446.0  8.1  22.3 
France  Adults  2 253  177.0  487.4  8.9  24.4 
Germany  Toddlers  81  65.8  155.0  3.3  7.8 
Germany  Other children  223  125.8  296.7  6.3  14.8 
Germany  Adolescents  991  223.9  710.0  11.2  35.5 
Germany  Adults  10 223  230.1  641.0  11.5  32.1 
Greece  Other children  791  114.8  300.7  5.7  15.0 
Hungary  Adults  1 071  192.3  460.7  9.6  23.0 
Ireland  Adults  956  180.0  445.9  9.0  22.3 
Italy  Toddlers  25 
(a)  79.9  245.1  4.0  12.3 
Italy  Other children  184  136.9  367.0  6.8  18.4 
Italy  Adolescents  243  169.7  495.4  8.5  24.8 
Italy  Adults  2 256  159.5  436.5  8.0  21.8 
Latvia  Other children  178  164.9  543.0  8.2  27.2 
Latvia  Adolescents  453  214.3  635.0  10.7  31.8 
Latvia  Adults  1 267  242.6  720.0  12.1  36.0 
Netherlands  Adults  743  220.6  545.0  11.0  27.3 
Netherlands  Toddlers  322  105.7  264.0  5.3  13.2 
Netherlands  Other children  955  132.9  330.7  6.6  16.5 
Spain  Adults  393  159.2  472.5  8.0  23.6 
Spain  Adolescents  85  181.8  562.8  9.1  28.1 
Spain  Adults  953  149.6  421.7  7.5  21.1 
Spain  Other children  396  146.4  329.0  7.3  16.5 
Spain  Adolescents  648  201.0  509.5  10.0  25.5 
Spain  Toddlers  13 
(a)  69.6  194.5  3.5  9.7 
Spain  Other children  148  138.1  365.0  6.9  18.3 
Spain  Adolescents  206  209.8  672.5  10.5  33.6 
Sweden  Adults  1 210  163.8  395.7  8.2  19.8 Safety of  UV-treated baker‘s yeast 
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Country  Age class  No of 
consumers 
Mean 
consumption 
(g) 
P97.5 
consumption  
(g) 
Mean 
consumption of 
vitamin D2 ( g) 
P97.5 
consumption 
of vitamin D2 
( g) 
Sweden  Other children  1 463  116.4  304.0  5.8  15.2 
Sweden  Adolescents  1 013  130.6  339.0  6.5  17.0 
United Kingdom Adults  1 706  164.7  408.3  8.2  20.4 
(a):  As the number of subjects is lower than 60, the 95
th and higher percentiles may not be statistically robust. 
(b):  ―Other children‖ comprises children aged 4 to 10 years.  Safety of  UV-treated baker‘s yeast 
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ABBREVIATIONS 
bw  body weight 
GMO  genetically modified organism  
NF(I)  Novel Food (Ingredient) 
NOAEL   no observed adverse effect level  
SCF  Scientific Committee on Food  
 